BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37541171)

  • 1. The natural history of ductal carcinoma in situ (DCIS) in simulation models: A systematic review.
    Poelhekken K; Lin Y; Greuter MJW; van der Vegt B; Dorrius M; de Bock GH
    Breast; 2023 Oct; 71():74-81. PubMed ID: 37541171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the natural history of ductal carcinoma in situ based on population data.
    Chootipongchaivat S; van Ravesteyn NT; Li X; Huang H; Weedon-Fekjær H; Ryser MD; Weaver DL; Burnside ES; Heckman-Stoddard BM; de Koning HJ; Lee SJ
    Breast Cancer Res; 2020 May; 22(1):53. PubMed ID: 32460821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.
    van Luijt PA; Heijnsdijk EA; Fracheboud J; Overbeek LI; Broeders MJ; Wesseling J; den Heeten GJ; de Koning HJ
    Breast Cancer Res; 2016 May; 18(1):47. PubMed ID: 27160733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.
    van Ravesteyn NT; van den Broek JJ; Li X; Weedon-Fekjær H; Schechter CB; Alagoz O; Huang X; Weaver DL; Burnside ES; Punglia RS; de Koning HJ; Lee SJ
    Med Decis Making; 2018 Apr; 38(1_suppl):126S-139S. PubMed ID: 29554463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ductal Carcinoma In Situ - Quo Vadis?
    Peltecu G
    Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.
    Sanders ME; Schuyler PA; Dupont WD; Page DL
    Cancer; 2005 Jun; 103(12):2481-4. PubMed ID: 15884091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A systematic review of international simulation models on the natural history of breast cancer: current understanding and challenges for Chinese-population-specific model development].
    Ma HM; Wang L; Shi JF; Ying JM; Zhu J; Chen LL; Yue XP; Gong JY; Li X; Wang JL; Dai M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Oct; 38(10):1419-1425. PubMed ID: 29060992
    [No Abstract]   [Full Text] [Related]  

  • 10. The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
    Théberge I; Vandal N; Guertin MH; Perron L
    Breast Cancer Res Treat; 2019 Apr; 174(2):525-535. PubMed ID: 30564969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
    Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
    Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the natural progression of non-invasive ductal carcinoma in situ breast cancer lesions using screening data.
    Weedon-Fekjær H; Li X; Lee S
    J Med Screen; 2021 Sep; 28(3):302-310. PubMed ID: 32854582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
    Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
    Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural history of ductal carcinoma in situ of the breast: a review.
    Erbas B; Provenzano E; Armes J; Gertig D
    Breast Cancer Res Treat; 2006 May; 97(2):135-44. PubMed ID: 16319971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the impact of 25 years of DCIS treatment.
    Ozanne EM; Shieh Y; Barnes J; Bouzan C; Hwang ES; Esserman LJ
    Breast Cancer Res Treat; 2011 Aug; 129(1):165-73. PubMed ID: 21390494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
    Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
    Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
    Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should low-risk DCIS lose the cancer label? An evidence review.
    Ma T; Semsarian CR; Barratt A; Parker L; Pathmanathan N; Nickel B; Bell KJL
    Breast Cancer Res Treat; 2023 Jun; 199(3):415-433. PubMed ID: 37074481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reoperation Rates in Ductal Carcinoma In Situ vs Invasive Breast Cancer After Wire-Guided Breast-Conserving Surgery.
    Langhans L; Jensen MB; Talman MM; Vejborg I; Kroman N; Tvedskov TF
    JAMA Surg; 2017 Apr; 152(4):378-384. PubMed ID: 28002557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.